Clinical queries: 0800 466 863

Education office: 0800 882 873


Pertussis, commonly known as whooping cough, is a highly contagious respiratory disease. It causes severe bouts of coughing, which may be accompanied by vomiting and a whooping sound. 

Pertussis can last up to three months and is sometimes referred to as the ‘hundred day cough.’ The symptoms are more obvious in children, because infants and adults are less likely to ‘whoop.’ 

Epidemics occur in New Zealand every three to five years and several thousand cases (mostly young children) are reported during each epidemic.

In older adolescents, adults and older people, pertussis often goes unrecognised and is under reported. Up to a third of adolescents and young adults with a persistent cough have evidence of recent pertussis infection.

    How you get it

    Pertussis is highly contagious and is spread by coughing and sneezing. The Bordetella pertussis bacterium infects around 90% of non-immune household contacts. School children and adolescents tend to be infected by another student or friend. Many babies catch it from their older siblings or parents, often before they are old enough to be fully vaccinated. Immunity wanes over time which means all adults are a potential source of infection for babies.

    A person with whooping cough is likely to be infectious from the week before they start coughing to three weeks after the cough begins.


    About 5 – 10 days (but sometimes up to 3 weeks) after catching whooping cough, the early symptoms start, including a runny nose, sneezing, slight fever and a mild irritating cough which lasts 1 to 2 weeks. This is the most infectious period. Babies in this phase can get apnoea (stop of breathing) attacks.

    The later stage symptoms include spasms of coughing followed by a big breath in or high-pitched ‘whoop’ sound in children. Infants and adults generally do not have the characteristic 'whoop'. Infants and young children often appear very unwell, and may turn blue and vomit with coughing bouts.

    The recovery stage may last for months. Although the cough eventually disappears after several weeks, coughing fits may recur whenever the patient suffers any later respiratory infection.


    There is no treatment for whooping cough. Antibiotics, such as erythromycin, can be prescribed during the early stages to reduce spread of the disease. They may reduce symptoms if given early enough.

    To ease coughing spasms

    • Warm drinks may be soothing and help break the coughing spasm
    • A humidifier in the bedroom may help (it must be cleaned every 2 or 3 days)
    • Saline nose drops to help remove thick mucus
    • Drink lots of clear fluids
    • Avoid coughing triggers, such as cigarette smoke, perfumes or pollutants


    Those most at risk of serious disease are infants under 12 months of age. Infants who do not receive on-time doses of pertussis-containing vaccine at the scheduled times of 6 weeks, 3 months, and 5 months are five times more likely to be hospitalised with pertussis than those babies who are vaccinated on time.

    Around half the babies who catch pertussis before the age of 12 months require hospitalisation and 1 or 2 in 100 of those hospitalised die from pertussis infection. Severe coughing can temporarily stop the oxygen supply to the brain (hypoxia). In around 2 in 1,000 children pertussis leads to permanent brain damage, paralysis, deafness or blindness. Secondary infections such as pneumonia and ear infections can occur.

    The disease is usually milder in adolescents and adults, consisting of a persistent cough similar to that found in other upper respiratory infections, although for some adults violent coughing will result in collapse, rib fracture or pneumonia. Both hospitalisations and deaths are likely to be under-estimated in adults.


    The best protection for infants is for their mother to be vaccinated during pregnancy followed by on-time immunisations for the infant at 6 weeks, 3 months and 5 months. Children are further protected with booster vaccines at four years and 11 years of age.

    When a pregnant woman is vaccinated against whooping cough her body develops high levels of antibodies (disease-specific protective proteins) which will pass through the placenta. These help protect the newborn from severe whooping cough for the first few months of life, until the infant has had their own three doses of vaccine and can make their own longer-term protection. A booster dose of a whooping cough vaccine (Boostrix®) is free for women from the second trimester of every pregnancy and recommended to be administered from 16 weeks, preferably during the second trimester, but at least two weeks before birth.

    Breastfeeding does not provide direct effective protection against whooping cough.

    All infants or children with pertussis should be excluded from early childhood services, school or community gatherings until they are well enough to attend and have either received five days of antibiotics or three weeks have elapsed since the onset of coughing spasms.

    It is also recommended that close family contacts of young infants, such as grandparents and fathers have a booster dose of pertussis vaccine to reduce spread of the disease. Older siblings should be up-to-date with their immunisations.

    From 1 July 2019, PHARMAC has extended eligibility to receive a free Boostrix vaccination to include parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days and who had not been exposed to maternal whooping cough immunisation at least 14 days before birth.


    Complications of disease

    • Dehydration, weight loss
    • Ear infection (otitis media)
    • Lack of oxygen (hypoxia) during coughing fits
    • Bleeding in the eye (sub-conjunctival haemorrhage)
    • Hospitalisation (5 infants in 10 cases aged under 12 months)
      • Slowed or stopped breathing (apnoea)
      • Pneumonia
      • Convulsions (seizures)
      • Death for 1—2 infants out of 100 hospitalised infants
      • Brain inflammation (encephalitis)
    • Violent coughing can result in urinary incontinence, ear infection, nose bleeds, collapse (syncope), pneumonia or broken ribs in adults

    Responses to combined vaccines (DTaP)

    Common responses

    • Decreased appetite
    • Vomiting or diarrhoea
    • Irritability, restlessness
    • Unusual crying
    • Limb swelling (after the 4th or 5th vaccine dose)

    Rare responses

    • Hives
    • Temporary low platelet count
    • Persistent inconsolable screaming in infants
    • Hypotonic, hyporesponsive episode (HHE) in infants
    • Convulsion

    As with any medicine, very rarely, severe allergic reactions occur following immunisation

    • Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics. 2017;139(5):e20164091.
    • Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, Combescure C, Othenin-Girard V, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis. 2016;62(7):829-36.
    • Eberhardt CS, Blanchard-Rohner G, Lemaître B, Combescure C, Othenin-Girard V, Chilin A, et al. Pertussis antibody transfer to preterm neonates after second- versus third-trimester maternal immunization. Clin Infect Dis. 2017;64(8):1129-32.
    • Edwards KM. Overview of pertussis: Focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(6):S104-8.
    • Edwards K, Decker M. Pertussis vaccines. In: Plotkin S, Orenstein W, Offit P, Edwards K, editors. Plotkin’s Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 711-61.
    • Grant CC, Roberts M, Scragg R, Stewart J, Lennon D, Kivell D, et al. Delayed immunisation and risk of pertussis in infants: Unmatched case-control study. BMJ. 2003;326(7394):852-3.
    • Halperin S, De Serres G. Pertussis. In: Evans A, Brachman P, editors. Bacterial infections of humans: Epidemiology and control. New York: Springer; 2009. p. 577-96.
    • Kerr JR, Matthews RC. Bordetella pertussis infection: Pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis. 2000;19(2):77-88.
    • Ministry of Health. Immunisation handbook [Internet]. Wellington: Ministry of Health; 2020 [updated 2020 September 25; cited 2020 September 28]. Available from:
    • van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J. 2005;24(5):S62-5.
    • Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5):S58-61.
    • Winter K, Cherry JD, Harriman K. Effectiveness of prenatal tetanus, diphtheria, and acellular pertussis vaccination on pertussis severity in infants. Clin Infect Dis. 2017;64(1):9-14.
    • Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis. 2011;11(7):557-70.

    Last updated: Jun 2022